United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eleven research firms that are presently covering the firm, MarketBeat.com r...

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the firm's stock in a transaction on Friday, December 12th. The stock was sold at an average...

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) reached a new 52-week high on Friday. The stock traded as high as $494.74 and last traded at $495.1590, with a volume of 203836 shares ...

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 11th. The stock was...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average p...

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at a...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

Cresset Asset Management LLC lowered its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 37.3% in the second quarter, according to the company in its most recent filing with th...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....